The PI3K/AKT/mTOR pathway is considered as a significant immune pathway and has been found to be commonly activated in human cancer [40], such as gastric, prostate, liver, breast, and colorectal cancer, thereby inhibition of this pathway becoming a potential candidate of molecular targeted therapy for malignancies [11, 41–43]. The gene discussed is MTOR; the disease is cancer.